Evidence map›Paper›PMID 40696832›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Real-world brain imaging in a population-based cohort enables accurate markers for dementia.

Reijo Sund, Juho Seppänen, Elaheh Moradi, Sami Väänänen, Jani Miettinen, Juhana Hakumäki, Toni Rikkonen, Heikki Kröger, Heli Koivumaa-Honkanen, Alina Solomon and 2 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Real-world brain imaging in a population-based cohort enables accurate markers for dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Reijo SundInstitute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0002-6268-8117
Juho SeppänenInstitute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Elaheh MoradiA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
Sami VäänänenDepartment of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland.
Jani MiettinenInstitute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Juhana HakumäkiInstitute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Toni RikkonenInstitute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Heikki KrögerInstitute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Heli Koivumaa-HonkanenInstitute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Alina SolomonInstitute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Jussi TohkaA.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
for Alzheimer's Disease Neuroimaging Initiative

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MICHAEL W WEINER · 2016 to 2026
$226.7M
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
AbbVieAlzheimer's AssociationAlzheimer's Drug Discovery FoundationAne and Signe Gyllenberg's Foundation 6671Araclon BiotechBiogenBristol-Myers Squibb CompanyCereSpir, Inc.CogstateElan Pharmaceuticals, Inc.Eli Lilly and CompanyEU Innovative Health Initiative Joint Undertaking AD-RIDDLE 101132933FujirebioGE HealthcareIXICO Ltd.Janssen Alzheimer Immunotherapy Research & DevelopmentJohnson & Johnson Pharmaceutical Research & DevelopmentLumosityMeso Scale DiagnosticsNeuroRx ResearchNeurotrack TechnologiesNIA NIH HHS U01 AG024904NIA NIH HHS U19 AG024904NIBIB NIH HHSNIH HHS U19 AG024904Novartis Pharmaceuticals CorporationPäivikki and Sakari Sohlberg FoundationPfizer Inc.Piramal ImagingResearch Council of Finland 338647Research Council of Finland 346934Research Council of Finland 351849Research Council of Finland 358944ServierState Research Funding of Kuopio University Hospital Catchment AreaTakeda Pharmaceutical CompanyTransition TherapeuticsUniversity of Eastern Finland Bioinformatics Center
6 · The paper itself

Abstract

introductionAlthough a vast amount of magnetic resonance imaging (MRI) data are collected for health care delivery, generating real-world evidence (RWE) in Alzheimer's disease and related dementias (ADRD) research is substantially limited by lack of methods and results showing how routine MRI scans can be used for ADRD imaging studies.

methodsWe compared three established ADRD biomarkers (total gray matter, hippocampal, and ventricular volumes) in four groups (normal, subjective complaints, mild cognitive impairment [MCI], and dementia) between the general population of women born in 1932-1941 in the Kuopio region of Eastern Finland (population-based Kuopio Osteoporosis Risk Factor and Prevention Study [OSTPRE] cohort, N = 14220) and a well-characterized research cohort (Alzheimer's Disease Neuroimaging Initiative [ADNI]).

resultsA total of 2434 brain MRI scans for 1885 women were collected between 2003 and 2022 by the public health care provider covering all residents in the region. The established biomarkers were overall aligned between these cohorts. DISCUSSION: Typical biomarkers extracted from real-world brain MRI scans collected over 20 years are suitable for generating RWE in ADRD research. HIGHLIGHTS: Real-world brain magnetic resonance imaging (MRI) is applicable for generating evidence in Alzheimer's disease and related dementias (ADRD) research. This is the first study comparing a real-world MRI cohort with an established research cohort reference. Provides a methodological framework for real-world evidence (RWE) ADRD studies that utilize routinely collected MRI scans.

Indexed as

Alzheimer DiseaseBrainCognitive DysfunctionDementiaMagnetic Resonance ImagingNeuroimagingAgedAged, 80 and overBiomarkersCohort StudiesFemaleFinlandHumansBiomarkersbrain imagingcognitive impairmentcognitive statusdementiahippocampal volumemagnetic resonance imagingmemory concernreal‐world datareal‐world evidencetotal gray matter volumeventricle volume

Identifiers

PMID40696832
PMCPMC12284318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.